QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research

These solutions aim to accelerate research into COVID-19 prevention and treatment by enabling deeper, more holistic insights into the biology of SARS-CoV-2.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, August 18, 2020
Information
Tags: 
Health, Medical devices, Infectious diseases, Research, Science, Pharmaceutical, Biotechnology, Animal diseases, Sarbecovirus, Zoonoses, Medical specialties, Bat virome, COVID-19, Severe acute respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome–related coronavirus, Coronavirus, Coronavir, Qiagen
Geotags: 
MARYLAND, SWITZERLAND, United States, Austria, Europe, Germany
⚠generated by AI ↴
Summary
Key Points: 


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease. The new products are an expansion of QIAGEN’s broad offering of sample technologies, diagnostic tests and instruments, and research tools for use in the global effort to combat the COVID-19 pandemic.

“These solutions aim to accelerate research into COVID-19 prevention and treatment by enabling deeper, more holistic insights into the biology of SARS-CoV-2. The more we understand the novel coronavirus and its development, the better equipped the world will be to stop the pandemic,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “We are partnering with leading institutes and companies to accelerate this vital research. Our new QIAseq SARS-CoV-2 Primer Panel and software pipeline will guide researchers into insights on the epidemiology, metatranscriptomics, immune response and pathways of the coronavirus – contributing to drug and vaccine development and public health strategies.”

QIAGEN’s new QIAseq SARS-CoV-2 Primer Panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to track viral genome changes in studying the epidemiology of virus outbreaks. The two-step process uses advanced QIAseq technologies to conduct reverse transcription and cDNA synthesis from a viral RNA sample, then generate libraries compatible with Illumina sequencing platforms. The workflow is faster and has lower-input requirements compared to hybrid capture solutions.

Please find the full press release here

For an overview of QIAGEN’s coronavirus testing solutions, please visit http://www.qiagen.com/coronavirus.

To explore QIAGEN’s NGS-specific solutions for COVID-19 research, please visit https://go.qiagen.com/CoronavirusNGS

For details of QIAGEN’s SARS-CoV-2 Whole Genome Sequencing Service, please visit https://www.qiagen.com/applications/genomic-services/sars-cov-2-whole-genome-sequencing-services

Copyright: 
Copyright Business Wire 2020